ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2392

Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

andre ramon1, helene Greigert2, corentin Richard3, claudie cladière4, coraline genet5, marion ciudad6, georges tarris7, laurent martin8, louis arnould9, catherine creuzot-garcher10, paul ornetti11, Sylvain Audia12, romain boidot3, jean-Francis Maillefert11, Bernard Bonnotte2 and Maxime Samson2, 1Department of Rheumatology, Dijon University Hospital, Dijon, France, 2Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 3Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, 4INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, 5INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 6INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 7Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, 8Department of Pathology, Dijon University Hospital, Dijon, France, 9Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, 10Department of Ophthalmology, Dijon University Hospital, Dijon, France, 11Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, 12Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France

Meeting: ACR Convergence 2023

Keywords: Dendritic cells, giant cell arteritis, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum between PMR and GCA, especially since a study reported mature arterial wall dendritic cells (DC) in patients with GCA or PMR. There are 3 main types of DC: plasmacytoid DC (expressing CD123), conventional DC (cDC) expressing CD141 (cDC1) or CD1c (cDC2), and monocyte-derived DC (mo-DC) expressing CD209 and CD14.This study aimed to identify, localize and characterize the phenotype of arterial DC in PMR and GCA.

Methods: Using temporal artery biopsies (TAB) from patients with PMR, GCA and healthy controls, bulk RNA-sequencing and RT-PCR analyses were performed to assess the level of expression of myeloid DC genes (CD141, CD1C, CD209, ITGAX), DC maturation genes (CD83, CD80/86, CCR7) and mature DC chemokine expression (CCL18, CCL19, CCL20, CCL21). Expression of markers of DC lineage (CD209), DC maturation state (CD83 and CCR7) and DC origin (CD14, CD68, CD1c, CD141) were also studied in TABs by immunofluorescence (IF).

Results: Forty-three patients were included (14 GCA, 15 PMR, 14 controls). TAB from GCA patients were characterized by a strong mature DC signature with high level of expression of DC associated genes (CD1C, ITGAX [coding CD11c] and CD209 [coding DC-SIGN]), DC maturation genes (CD83, CCR7, CD80/CD86) and DC chemokine genes (CCL18, CCL19, CCL20). In PMR arteries, the DC signature was more heterogeneous: a few arteries expressed CD1C and CD141 but none expressed DC maturation genes. Healthy arteries were characterized by the absence of expression of DC associated genes and mature DC genes (figure 1). In GCA arteries, IF analysis revealed that the three arterial layers were heavily infiltrated by CD209+ cells. These cells also expressed CD14 and often CD68, thus fitting with mo-DC (CD209+CD14+CD68–) or macrophages (CD209+CD14+CD68+). Some of these cells expressed maturation markers of DC (CD83 and CCR7). However, no CD1c or CD141 cells were found in the arterial wall by IF. In PMR and control arteries, no DC were found by IF. Transcriptomic analysis revealed that GCA arteries expressed many genes involved in the differentiation of monocytes into mo-DC, including CSF2, CYBA, IRF4, AHR, WNT5A, and FZD2.

Conclusion: This work demonstrates the presence of mature CD209+CD83+CCR7+ DCs within the arterial wall in GCA but not in PMR or healthy arteries. The phenotype of these DCs mainly fits with mo-DCs. In PMR, the DC signature is more heterogeneous without expression of DC maturation markers.

Supporting image 1

Figure 1: “DC signature” in GCA, PMR and control arteries.

Myeloid dendritic cell genes are defined as genes that characterize human dendritic cells: CD1C (coding CD1c), THBD (coding CD141), CD209, ITGAX (coding CD11c).
DC maturation associated genes are defined by the process in which antigen-activated dendritic cells acquire the specialized features of a mature conventional dendritic cell. Mature conventional dendritic cells upregulate the surface expression of MHC molecules, chemokine receptors and adhesion molecules, and increase the number of dendrites (cytoplasmic protrusions) in preparation for migration to lymphoid organs where they present antigen to T cells: CD83, CD80, CD86, CCR7, CCL18, CCL19, CCL20, CCL21, TLR4, IRF3.


Disclosures: a. ramon: None; h. Greigert: None; c. Richard: None; c. cladière: None; c. genet: None; m. ciudad: None; g. tarris: None; l. martin: None; l. arnould: None; c. creuzot-garcher: None; p. ornetti: None; S. Audia: None; r. boidot: None; j. Maillefert: None; B. Bonnotte: None; M. Samson: ARGENX, 2, Boehringer-Ingelheim, 2, CHUGAI, 2, CSL Vifor, 2, GlaxoSmithKlein(GSK), 2, NOVARTIS, 2, 5.

To cite this abstract in AMA style:

ramon a, Greigert h, Richard c, cladière c, genet c, ciudad m, tarris g, martin l, arnould l, creuzot-garcher c, ornetti p, Audia S, boidot r, Maillefert j, Bonnotte B, Samson M. Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/characterization-of-arterial-dendritic-cells-in-polymyalgia-rheumatica-and-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-arterial-dendritic-cells-in-polymyalgia-rheumatica-and-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology